Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 12/20 | 0.49 |
| ▸ | OPRK1 | P41145 | 12/20 | 0.49 |
| ▸ | NMUR2 | Q9GZQ4 | 3/20 | 0.46 |
| ▸ | NMUR1 | Q9HB89 | 3/20 | 0.46 |
| ▸ | APLNR | P35414 | 1/20 | 0.45 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.44 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.44 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.44 |
| ▸ | RAMP3 | O60896 | 2/20 | 0.43 |
| ▸ | CALCR | P30988 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16508529 | 0.93 | OPRM1 (0.57) | OPRM1OPRK1NMUR2NMUR1APLNR | |
| SCHEMBL16508479 | 0.90 | OPRM1 (0.51) | OPRM1OPRK1NMUR2NMUR1APLNR | |
| SCHEMBL16508575 | 0.87 | OPRM1 (0.56) | OPRM1OPRK1APLNR | |
| SCHEMBL16508578 | 0.86 | OPRM1 (0.49) | OPRM1OPRK1NMUR2NMUR1APLNR | |
| SCHEMBL16508495 | 0.86 | OPRM1 (0.49) | OPRM1OPRK1NMUR2NMUR1APLNR | |
| SCHEMBL16508551 | 0.86 | OPRM1 (0.56) | OPRM1OPRK1APLNR | |
| SCHEMBL16508494 | 0.84 | OPRM1 (0.51) | OPRM1OPRK1APLNR | |
| SCHEMBL31088262 | 0.84 | RAMP3 (0.48) | OPRM1OPRK1NMUR2NMUR1MAPK8 | |
| SCHEMBL16508585 | 0.83 | OPRM1 (0.52) | OPRM1OPRK1APLNR | |
| SCHEMBL30495666 | 0.83 | NMUR2 (0.46) | OPRM1OPRK1NMUR2NMUR1MAPK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110300167-A1 | CXCR5 RECEPTOR COMPOUNDS | ANCHOR THERAPEUTICS, INC. | 2011-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110300167-A1 | CXCR5 RECEPTOR COMPOUNDS | CXCR5, CXCR1, CCR5 | OPRM1 1105/4885OPRK1 456/4885NMUR2 2266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.